Use access key #2 to skip to page content.
$3.51 0.25 (7.67%)
7/8/2008 4:00 PM

ACADIA Pharmaceuticals, Inc. (ACAD)

CAPS Rating:
**

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

View All Commentary (ACAD)

Recs

1

Avatar zzlangerhans (78.80) Submitted: 9/27/07 1:43 AM : Outperform Start Price: $15.28 ACAD Score: -60.21

I like the way this company is advancing its two major products aggressively. Positive catalysts within next year are interim data for phase III trial of pimavanserin and phase IIb trial of ACP-104. Company also has other drugs in early development.

Report this Post Replies: 0 | Reply

Featured Broker Partners